Andrew Obenshain, bluebird bio CEO
Bluebird joins the layoff flock to reality as gene therapy biotech sheds staff to save itself
Bluebird bio is laying off about 30% of its workforce to save itself before the FDA decides the fate of two of its gene therapies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
